Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present CardioGenics Holdings Inc. (OTC: CGNH).

Full DD Report for CGNH

You must become a subscriber to view this report.


Recent News from (OTC: CGNH)

CardioGenics Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap
MISSISSAUGA, ON--(Marketwired - Nov 4, 2015) - CardioGenics Holdings Inc. ( OTCQB : CGNH ), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it, a...
Source: Marketwired
Date: November, 04 2015 13:46
CardioGenics Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap
MISSISSAUGA, ON--(Marketwired - Oct 5, 2015) - CardioGenics Holdings Inc. ( OTCQB : CGNH ), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it has e...
Source: Marketwired
Date: October, 05 2015 09:01
CardioGenics Enters Into Manufacturing Agreement With Ontario-Based Plasticap
MISSISSAUGA, ON--(Marketwired - Aug 25, 2015) - CardioGenics Holdings Inc. ( OTCQB : CGNH ), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it has ...
Source: Marketwired
Date: August, 25 2015 09:02

 


About CardioGenics Holdings Inc. (OTC: CGNH)

Logo for CardioGenics Holdings Inc. (OTC: CGNH)

Based in Ontario, Canada, CardioGenics is engaged in the development and marketing of a point of care testing device and several diagnostic test products. The point of care testing device is less expensive, easier to use, network ready, provides faster results, and provides lab quality results within minutes with large advantages over competing products on the market today, including improving patient outcomes and reducing costs associated with such healthcare.

 

Contact Information

 

 

Current Management

  • Yahia Gawad / CEO
    • Yahia was a cofounder of Syn X previously Skye Pharmatech where he held the position of VicePresident, Medical Affairs and prior to that, he was Director of Clinical Research at Spectral Diagnostics Inc. For the last years, he has been working extensively on cardiac diagnostic test products, which he took from concept and bench development to commercialization, through regulatory approval processes. Dr. Gawad is a Physician/Scientist with primary training in Cardiology, Biochemistry and Immunology.
  • Linda J. Sterling / Secretary
    • Linda has been managing CardioGenics legal affairs since . Linda has been in the legal community in the capacity as a Law Clerk with both Stikeman Elliott LLP and Davies Ward Phillips amp Vineberg LLP since . She developed expertise with both public and private company legal compliance and has been responsible for CardioGenics compliance and maintenance of corporate governance since . She is licensed as a Legal Executive F.Inst.L.C.O. with the Institute of Law Clerks of Ontario, of which she is a member. She has held the position of CEO and director of Sterling Studios since .
  • James Essex / CFO
    • James has been with CardioGenics since . He founded Hunter amp Associates Inc. in , a private financial consulting firm. Previously, he was a coowner, President and COO of Calais Investigations, Inc., a private company from to , a Vice President of Confederation Trust and a Vice President of Chemical Bank of Canada now Chase Manhattan Bank of Canada from through .
  • Neil J. Tabatznik / Chairman, Independent Director
    • Neil has been with CardioGenics since . He was the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in , and has seen rapid growth from to million in years. The Arrow Group has sales operations in continents and employs more than people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. , which was acquired by Merck KGaA in and is now a part of Mylan Inc. the world s third largest generic and specialty pharmaceutical company. He was a BarristeratLaw in London and was called to the Bar of England and Wales in . He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.
  • Yahia Gawad / Director
    • Yahia was a cofounder of Syn X previously Skye Pharmatech where he held the position of VicePresident, Medical Affairs and prior to that, he was Director of Clinical Research at Spectral Diagnostics Inc. For the last years, he has been working extensively on cardiac diagnostic test products, which he took from concept and bench development to commercialization, through regulatory approval processes. Dr. Gawad is a Physician/Scientist with primary training in Cardiology, Biochemistry and Immunology.
  • Karim Murabet / Independent Director
    • Karim has extensive business experience in diverse fields. He began his career as a professional soccer player around the world and went on to work in the sporting goods industry as the owner of Lanzera Italia. His passion for sports also led him to be a football manager in various countries. As an investor, he is currently coowner of Libyan Italian Real Estate Investment Co. and a consultant and advisor to Gruppo Bonifaci, one of Italy s largest real estate developers, based in Rome. Karim currently resides in the United Arab Emirates and is a Partner and Director responsible for business development and public relations in ICap Group FZC, a property development, architecture, hotel management and investment company registered in the United Arab Emirates. Karim is a graduate of College du leman in Versoix, Switzerland and received a BA in human behavior and later an MBA in business from U.S. International UniversitySan Diego.
  • Linda J. Sterling / Director
    • Linda has been managing CardioGenics legal affairs since . Linda has been in the legal community in the capacity as a Law Clerk with both Stikeman Elliott LLP and Davies Ward Phillips amp Vineberg LLP since . She developed expertise with both public and private company legal compliance and has been responsible for CardioGenics compliance and maintenance of corporate governance since . She is licensed as a Legal Executive F.Inst.L.C.O. with the Institute of Law Clerks of Ontario, of which she is a member. She has held the position of CEO and director of Sterling Studios since .

Current Share Structure

  • Market Cap: $2,217,302 - 03/16/2018
  • Authorized: 150,000,000 - 11/03/2017
  • Issue and Outstanding: 110,865,104 - 11/03/2017

 


Recent Filings from (OTC: CGNH)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: November, 13 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: June, 15 2016
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2016
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: April, 11 2016
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 31 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 28 2016
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: March, 17 2016
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 26 2016
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: January, 29 2016
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 09 2015

 

 


Daily Technical Chart for (OTC: CGNH)

Daily Technical Chart for (OTC: CGNH)


Stay tuned for daily updates and more on (OTC: CGNH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CGNH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CGNH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of CGNH and does not buy, sell, or trade any shares of CGNH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/